Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01374568 · ClinicalTrials.gov registry record · Phase 4
Changes in Bone Turnover With Increased Incretin Hormone Exposure
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT01374568 is a Phase 4 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants.
The verdict
NCT01374568, a Phase 4 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.
Interventions
- OTHER Placebo
- DRUG sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01374568
The ClinicalTrials.gov registry entry for NCT01374568 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01374568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01374568 about?
NCT01374568 is a clinical study titled "Changes in Bone Turnover With Increased Incretin Hormone Exposure". The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.
What is the current status of trial NCT01374568?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2010-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01374568?
The interventions under investigation include: Placebo (OTHER), sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01374568?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.